Genome-wide CRISPR screen identifies ACSL3 as a regulator of lipotoxicity and progression of MASLD
ACSL3 is a central regulator of lipotoxic hepatocyte injury and MASLD progression, mechanistically linking lipid-droplet biogenesis to apoptosis and inflammatory niche formation. These data suggest that ACSL3 is a promising therapeutic target and support further translational studies to evaluate ACSL3 modulation in steatotic liver disease.
Authors
- Kosuke Yusa (ORCID: https://orcid.org/0000-0002-3442-021X)
- Yasuteru Kondo (ORCID: https://orcid.org/0000-0001-5935-4346)
- Takahiro Kodama (ORCID: https://orcid.org/0000-0002-6250-1324)
- Hideharu Nagasawa
- Yuta Myojin (ORCID: https://orcid.org/0000-0003-0360-9703)
- Yoshinobu Saito (ORCID: https://orcid.org/0000-0002-0624-0449)
- Hideo Shindou (ORCID: https://orcid.org/0000-0002-3443-913X)
- Kazuhiro Murai (ORCID: https://orcid.org/0000-0001-8634-2922)
- T. Takehara
- Hayato Hikita (ORCID: https://orcid.org/0000-0003-2488-7315)
- Ryo Takahashi (ORCID: https://orcid.org/0000-0002-5360-4313)
- Tomomi Yoshida-Hashidate
Institutions
- Osaka Gakuin University (JP)
- Kyoto University (JP)
- National Center for Global Health and Medicine (JP)
- Ikeda Municipal Hospital (JP)
- Kansai Rosai Hospital (JP)
- Sendai City Hospital (JP)
- Sendai Shakai Hoken Hospital (JP)
- Sendai Kousei Hospital (JP)
- The University of Tokyo (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1097/hc9.0000000000000884
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00